Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

2021 ◽  
Author(s):  
Arne Vandevelde ◽  
Walid Chayoua ◽  
Bas Laat ◽  
Jean‐Christophe Gris ◽  
Gary W. Moore ◽  
...  
Keyword(s):  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Analytical Platforms

The clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome

2020 ◽  
Author(s):  
Dong-mei Yin ◽  
Philip de Groot ◽  
Marisa Ninivaggi ◽  
Katrien M.J. Devreese ◽  
Bas de Laat
Keyword(s):  
Antiphospholipid Syndrome ◽  
Clinical Relevance ◽  
Antiphospholipid Antibodies ◽  
Odds Ratio ◽  
Lupus Anticoagulant ◽  
Solid Phase ◽  
Control Group ◽  
Domain I ◽  
Normal Controls ◽  
Better Than

Background: Patients positive for three types of antiphospholipid antibodies (aPLs) (triple positivity) have been identified at a high risk for thrombotic events. However, the clinical significance of isolated lupus anticoagulant (LAC) positivity is debated. Objectives: To investigate the clinical relevance of isolated LAC. Patients/Methods 456 patients were enrolled in this study; 66 antiphospholipid syndrome patients and 390 control patients. The control group existed of autoimmune patients (n=91), patients with thrombosis but without aPLs (n=127) and normal controls (n=172). The criteria LAC, anti-cardiolipin (anti-CL) and anti-beta2glycoprotein I (anti-β2GPI) IgG and IgM and the non-criteria IgA anti-CL and anti-β2GPI, anti-domain I (anti-DI) of β2GPI IgG and anti-phosphatidylserine/prothrombin (anti-PS/PT) IgG and IgM were detected according to the ISTH guidelines for solid phase assays. Results: 70 patients were positive for LAC, of which 44 were negative for both anti-β2GPI and anti-CL. We found that isolated LAC proved to be strongly associated with vascular thrombosis (Odds ratio (OR) (95% CI) 7.3 (3.3-16.1)), even better than triple positive samples (OR 4.3 (1.6-12.2)). The titers of the anti-PS/PT IgG and IgM were significantly higher in triple positivity samples compared to samples with isolated LAC positivity. The majority of single LAC positives were anti-PS/PT negative. We observed that LAC positivity was weaker in isolated LAC positive patients compared to LAC activity in triple positive patients. Conclusions: Isolated LAC was highly associated with thrombosis. The presence of anti-PS/PT could not explain LAC positivity in isolated LAC. Isolated LAC showed a weaker LAC activity compared to triple positive patients.

The Influence of Antiphospholipid Antibodies on the Pregnancy Outcome of Patients With Recurrent Spontaneous Abortion

2001 ◽  
Vol 7 (4) ◽  
pp. 281-285 ◽  
Author(s):  
L. Heilmann ◽  
G.-F. v. Tempelhoff ◽  
S. Kuse
Keyword(s):  
Pregnant Women ◽  
Intravenous Immunoglobulin ◽  
Spontaneous Abortion ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Standard Therapy ◽  
Loss Rate ◽  
Fetal Loss ◽  
Negative Group ◽  
History Of

Several therapeutic regimens have been proposed for women with recurrent spontaneous abortion (RSA) and antiphospholipid antibodies (APA). Conflicting results have been reported about women with history of RSA, positive APA, and failure of standard therapy. To evaluate the use of intravenous immunoglobulin in RSA patients with APA and history of treatment failure, we initiated a study with standard therapy (aspirin and low-molecular- weight heparin) and intravenous immunoglobulin. We used an enzyme-linked immunosorbent assay (ELISA)test to screen IgG and IgM anticardiolipin antibodies, and a diluted Russel viper venom time assay for the lupus anticoagulant activity. Altogether. 66 pregnant women with positive APAs at the first visit could be included. Patients with hereditable thrainbaghilic factors were excluded. After confirmation of the pregnancy, women received a basis immunization of 0.3 g/kg immunoglobulin in a 4-week cycle until the 28th to 32nd week of gestation. All patients received 100 mg/d aspirin and 3,000 anti-Xa U/d certoparin. Among the 66 pregnant women, 17 were persistently autoantibody positive (25.8%), of whom 11 (16.7%) were ACA positive alone, 2 (3%) were lupus anticoagulant positive, and 4 (6.4%) had both antibody types. A total of 49 patients had positive APAs at the initial test, but were negative for ACA and lupus anticoagulant at the second test administered approximately 5 weeks after the start of therapy. We described this group in our following observation as "antibody negative." Sixteen of the 17 autoantibody-positive patients (94.1 %) were delivered of live infants compared with 40 patients (81.6%) in the antibody-negative group (odds ratio [OR]: 1.2; 95% CI: 0.98 to 1.4). The overall miscarriage rate was 12.1% and the fetal loss rate was 15.2%. Four patients (25%) in the antibody-positive group developed symptoms of preeclampsia and fetal growth retardation compared with four patients (9.8%) in the antibody-negative group. In conclusion. we see a reduction of the fetal loss rate in patients with RSA and positive APA (5.8%) compared with APAnegative (18.4%) women with the same therapy (OR: 0.3; 95% CI: 0.04 to 2.3).

scholarly journals Hemostasis system and immunomorphologic state of placenta under presence of antiphospholipid antibodies in plasma with consideration of their class and pregnancy outcome

2004 ◽  
Vol 53 (1) ◽  
pp. 22-26
Author(s):  
N. G. Kosheleva ◽  
L. В. Zubzhitskaia ◽  
О. N. Arzhanova ◽  
О. V. Tyshkevich ◽  
Y. Gromyko ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Recurrent Miscarriage ◽  
Anticardiolipin Antibodies ◽  
Research Groups ◽  
Hemostasis System ◽  
Autoimmune Antibodies ◽  
Glycoprotein I ◽  
Tissue Damages

The present study was undertaken to investigate hemostasis system of 197 women with recurrent miscarriage: Analysis placentas by immunomorphology are studied of 41 women and of 52 women with autoimmune antibodies to 2-glycoprotein-I (2-GPI) in placenta. There was exposed hyperactivation platelets blood of all women with antiphospholipid antibodies irrespective of groups with significantly was increased at the beginning of pregnancy and progressed with growing gestation. As result of investigation it is determined certain connection between outcome of pregnancy and activation degree platelets blood in vasculars. Was found absence influence anticardiolipin antibodies (aCL) on plasmocoagulative link hemostasis. The circulation of lupus anticoagulant (LA) was accompanied indication of hypercoagulation. In all research groups was determined significant oppression of fibrinolisis. Analysis placentas by immunomorphology was determined significantly tissue damages with LA and 2-GPI-dependent aCL.

scholarly journals Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab

2019 ◽  
Vol 12 (3) ◽  
pp. e224636
Author(s):  
Ziyang Liu ◽  
Merry Markham ◽  
Molly W Mandernach
Keyword(s):  
Prothrombin Time ◽  
Successful Treatment ◽  
Partial Thromboplastin Time ◽  
Antiphospholipid Antibodies ◽  
Patient Population ◽  
Lupus Anticoagulant ◽  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Small Lymphocytic Lymphoma ◽  
Upfront Therapy

A 46-year-old man presented with splenomegaly, abdominal adenopathy and profoundly elevated prothrombin time and partial thromboplastin time. He was diagnosed with marginal zone lymphoma (MZL) and small lymphocytic lymphoma, and the abnormal coagulation studies were secondary to the presence of a lupus anticoagulant. Optimal upfront therapy for MZL has not been established, and the incidence of antiphospholipid antibodies (APLA) in this patient population is rare. Following treatment with six cycles of bendamustine and rituximab with 2 years of rituximab maintenance, our patient remained in remission and his coagulation studies normalised. This report describes a case of successful treatment of APLA associated with MZL that resolved after treatment of the lymphoma.

scholarly journals Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

2020 ◽  
Vol 18 (11) ◽  
pp. 2828-2839
Author(s):  
Katrien M. J. Devreese ◽  
Philip G. Groot ◽  
Bas Laat ◽  
Doruk Erkan ◽  
Emmanuel J. Favaloro ◽  
...  
Keyword(s):  
International Society ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant

scholarly journals Antiphospholipid Antibodies in Patients With Lupus Anticoagulant Prozone Effect

2019 ◽  
Vol 153 (2) ◽  
pp. 229-234
Author(s):  
Colin H Murphy ◽  
Jing Jin ◽  
James L Zehnder
Keyword(s):  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Antibody Testing ◽  
Effect Factor ◽  
Factor Ii ◽  
Antibody Specificities ◽  
Prozone Effect

Abstract Objectives Lupus anticoagulant (LAC) is typically associated with thrombosis but also rarely with hemorrhage. Some patients exhibit a prozone effect on LAC testing. Antiphosphatidylserine/prothrombin (aPS/PT) antibodies may provide a mechanism for both hemorrhage and prozone effect. Our goal was to evaluate whether antibody specificities, isotypes, and titers were associated with LAC prozone effect, factor II levels, hemorrhage, and thrombosis. Methods Patients with prozone effect noted on LAC testing were entered into a database over 3 years. Factor II activity and aPS/PT antibody testing were performed when a sufficient residual sample was available. Results All patients with LAC prozone effect and antibody testing were positive for at least 1 class of aPS/PT antibodies. In addition, aPS/PT IgG titers were significantly associated with thrombosis and significantly inversely associated with factor II levels. Conclusions In prozone effect patients, aPS/PT antibodies are associated with LAC prozone effect as well as thrombosis and decreased factor II levels.

Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: Comparison of three lupus anticoagulant assays and anticardiolipin-elisa in 188 patients

1992 ◽  
Vol 65 ◽  
pp. S120
Author(s):  
T. Jouhikainen ◽  
H. Julkunen ◽  
O. Vaarala ◽  
M. Leirisalo-Repo ◽  
E. Stephansson ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Systemic Lupus

scholarly journals https://www.immunologyresearchjournal.com/articles/association-of-lupus-anticoagulant-with-brain-atrophy-in-gulf-war-illness-gwi.html

2021 ◽  
Vol 5 (2) ◽  
pp. 47-50
Author(s):  
Lisa M. James ◽  
Peka Christova ◽  
Rachel A. Johnson ◽  
Brian E. Engdahl ◽  
Scott M. Lewis ◽  
...  
Keyword(s):  
Gray Matter ◽  
Brain Atrophy ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Brain Volume ◽  
Gulf War ◽  
Cerebral White Matter ◽  
Clotting Time ◽  
Gulf War Illness ◽  
Cortical Gray Matter

Separate lines of research have documented brain atrophy and evidence of autoimmune mechanisms in Gulf War Illness (GWI), including the presence of lupus anticoagulant (LAC), in veterans with GWI. Here we evaluated the possible association of LAC and brain volume in veterans with GWI. The presence of LAC was determined using Silica Clotting Time and dilute Russell’s Viper Venom Time assays. MRI data was acquired using a Philips 3T MR scanner from which total gray matter, total cortical gray matter, total subcortical gray matter, and total cerebral white matter were derived. The results demonstrated a statistically significant reduction of brain volume in all regions tested in GWI veterans with positive LAC, as compared to those without LAC. These findings add to the literature implicating autoimmune mechanisms in GWI and point to the presence of prothrombotic antiphospholipid antibodies as contributing to brain atrophy in GWI.

scholarly journals Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

1992 ◽  
Vol 90 (3) ◽  
pp. 1100-1104 ◽  
Author(s):  
R A Roubey ◽  
C W Pratt ◽  
J P Buyon ◽  
J B Winfield
Keyword(s):  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Anticoagulant Activity ◽  
Glycoprotein I ◽  
Beta 2

scholarly journals La sindrome da anticorpi anti-fosfolipidi: un mare di autoanticorpi

2021 ◽  
Vol 24 (6) ◽  
pp. 187-187
Author(s):  
Eleonora Dei Rossi
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
High Titer ◽  
Small Vessel ◽  
Pulmonary Thrombosis ◽  
Systemic Disorder ◽  
Vessel Thrombosis

Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous or small vessel thrombosis in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant or moderate-high titer anticardiolipin or anti-β2Glycoprotein I antibodies. The paper describes a case of a 16-year-old girl with recurrent pulmonary thrombosis and antiphospolipid syndrome.

Sign in / Sign up

Export Citation Format

Share Document